Dr. Peter Stafford, a U.S. physician, was discharged from a German hospital on Saturday, June 6, 2026, after recovering from Ebola [1].
Stafford's recovery highlights the efficacy of emerging medical interventions against the virus. His case provides critical data on the use of experimental treatments in a clinical setting for healthcare workers exposed to the disease in high-risk zones.
Stafford contracted the virus while working for a missionary group in the Democratic Republic of Congo [2]. He was transported to the Charité university hospital in Berlin, Germany, where he received specialized care. According to hospital records, he was discharged after 17 days of medical care [3].
Medical staff utilized non-standard protocols to treat the physician. "We administered experimental therapies that are currently being trialed for this strain of Ebola," said Dr. Martina Keller, an infectious-disease specialist at Charité [4].
The hospital confirmed that the patient's condition had stabilized completely before his release. "He is now in good health and will be discharged today," said a spokesperson for Charité hospital [5].
Stafford expressed gratitude for the medical team and his support system upon his release. "I am grateful for the care I received and look forward to reuniting with my family," Dr. Peter Stafford said [6]. Reports indicate that five family members traveled to be with him during the discharge process [7].
The physician's journey from the Democratic Republic of Congo to Berlin underscores the global coordination required to treat highly infectious diseases. By utilizing a specialized isolation unit at Charité, German health officials were able to manage the risk to the public while providing the necessary life-saving interventions [1].
“"We administered experimental therapies that are currently being trialed for this strain of Ebola,"”
The successful treatment of Dr. Stafford using experimental therapies suggests a positive trend in the development of targeted Ebola interventions. Because he was treated at a high-capacity facility like Charité, the case demonstrates the importance of specialized biocontainment infrastructure in preventing local outbreaks while treating patients who have contracted the virus abroad.
